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The Russian regisb'y of cystic fibrosis 
T. Kapoustina 1, N. Kashir skaia 2, N. Kapr alloy 9, A. Vor onkova 2 
Russian State Medical University, Research Centre for Medical Genetics 2, 
Moscow, Rgtssia 
The Russian registry of Cystic Fibrosis began collecting data on Russian cystic 
fibrosis patients in 2CO1. The database of regisiry consists of 463 parameters, which 
are grouped in 55 tables (438 parameters are dynamic). 
The registi3~ consists of the following sections: personal data, anamnesis, data of 
out patient examination (every 3 months), data of hospitalization. Now registi3~ 
contains the information on 556 patients (295M/261F aged 3mth 32yrs), 503 
patients alive, 53 (9,5%) died. 178 (32%) patient constantly live at Moscow and 
Moscow region. 
The following data were received with the help of the registry: severe CF symptoms 
have 377 (68%) patients, 544 (98 %) have pancreatic insufficiency. The most often 
complications CF were liver cirdlosis 77 ( 13,8 %), chronic lung hear t 48(8,6%), 
diabetes mellitus 15 (2,7%) patients. Genotype analysis had been performed on 
235 (42%) of these patients: 176 carries delF508 mutation (gomozygous for 
delF508 81 (34%), 10 (4,2%) patients cmries CFTR dele 2,3(21kb). The basic 
treatment includes pancreatic enzymes (100% patients), vitamins (100%), 
mucolytic (90%), UDCA (88%), rhDNase (30%). 
The Russian CF registry will allow to quickly analyze the information on all 
patients observed at the Russian CF centre, and also to exchange the information 
with the regional CF centers. 
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Presymptomatic diagnosis of CF in the first 2 months improves 
outcome 
E.J. Sims 1"~, J. McCormick 1, G. Connett ~, G. Mehta 1, A. Mehta 1 
Data supplied by the Directors of Specialist CF Centers in the UK 
~ UK CF Database, University of Dundee, UK; 2Dept. Population Health, University 
of East Anglia, Norwich, UK; SDept. Paediatrics, Southampton University 
Hospitals NHS Trust, UK 
Background: Clinical vigilance may be considered ml adequate substitute for 
newborn screening (NBS) for diagnosing cystic fibrosis (CF). 
Aims: To test whether pre symptomatic diagnosis by NBS (dia~aosis <2 months) 
provided clinical benefit compared with late clinical diagnosis (>2 months; LCD) 
or early clinical diagnosis (< 2 months; ECD). 
Methods: Using the UK CF Database, NBS, ECD or LCD AF508/AF508 patients, 
aged 1 10 years were compared in a retrospective r peated measures cohort study. 
Alter age matching, 291 sets of data from 2C(K) 2CO2 were identified for each of 167 
ECD, 171 LCD and 144 NBS patient cohorts. Height (Fit) and weight 0Nt) z scores, 
Shwachmml Kulczyki (SK) morbidity scores, and FEV 1% predicted were 
compared. To limit potential bias due to repeated measures, medimls were compared 
using Mann Whitney two sample rmlk test using the most recent data for each 
patient. After matching by age and year of data collection, 133 patients per cohort 
were identified. 
Results: For the 291 dataset cohorts, NBS compared to LCD, but not ECD, had 
higher Ht z scores mid SK scores up to 8 years and 5 years of age, respectively. 
Indeed, for the 133 patient cohorts, NBS had significantly higher mediml Ht z score 
and SK score compared to the LCD cohort (0.38;95% CI: 0.20.56; and 4; 95% CI: 
2 5, respectively ). No differences in Wt z score or FEV 1 were found. No differences 
were found between NBS and ECD or ECD and LCD. 
Conclusions: NBS offers clinical benefits over LCD. Whether these benefits are 
due to nutritional or therapeutic differences i taflalown. 
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Outcome of pregnancies in Polish women with CF 
A. Kor zeniewska 1,K. Smejda 1, ~,V. S korupa 9, I. Stehnach 1 
~Department of Pediatrics and AIIergy, M Curie Hospital, ZgierT. Poland, 2First 
Department of Lung Diseases, National Institute of TB and Lung Diseases, Warsaw, 
Polatul 
Aim: The purpose of this study was to investigate the consequences of pregnancy 
on women with CF and to clarify the impact of the disease on newborn health. 
Methods: It was a retrospective study; a postal questionnaire was sent to 12 woman 
having a registered pregnancy in National Cystic Fibrosis Registry between 1984 
and 2CO4. 
Results: There was a 100% response rate. 16 pregnancies have been reported (4 
patients had two pregnancies); there were 16 live births of which 11 (69%) were 
premature, 10 (62%) of newborns had low weight. There was one neonatal death. 
The mean prepregnancy FEV1 (% predicted) and BMI (kg/m 2) were 56,6+14,8% 
(range 35 95) and 19,9+1,5 (range 18 23) respectively. The mean FEV1 during 
pregnancy was 47,7+15,1% (range 23 87), mean maternal weight gain during 
pregnancy was 5,5kg. There was a significant decline in FEV1 during pregnancy 
(16,6+6,4 %, p<0,05) as compared to prepregnancy values. Two women had 
diabetes mellitus and two developed gest ational diabetes. Mean postpregnancy (12 
months after delivery) FEV1 was 54,1+18,8% (range 22 103) and mean BMI was 
18,7+1,8 kg/m 2 (range 15 22). There was a significant postpregnancy decline in 
FEV1 (6,2+10,6%, p 0,027) and in BMI (1+1,14 kg/m ~, p<0,01) as compared to 
prepregnancy values. Microbiological status remains unchanged. 11 patients alive; 
one patient died 11 years after delivery. The mean follow up time was 8,8+6,7 years 
(range 2 23). 
Conclusions: Pregnancy was well tolerated in our population of CF women, 
although affected the rate of yearly decline in FEV1 and BMI. hlcreased risk of 
premature and low newborn weight were observed. All pregnancies in CF women 
should be planned and monitored by CF team. 
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Diagnosis of CF by newborn screening reduces subsequent burden 
of treabnent 
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Data supplied by the Directors of Specialist CF Centers in the UK 
Background: Increased therapy may be responsible for improved clinical outcomes 
associated with newborn screening (NBS) for cystic fibrosis (CF) compared with 
clinical diagnosis. 
Aims: To test whether NBS (diagnosis <2 months) was associated with a higher 
treatment burden compared with late clinical diagnosis (>2 months; LCD) or early 
clinical diagnosis (< 2 months; ECD). 
Methods: Using the UK CF Database, NBS, ECD or LCD AF508/AF508 patients, 
aged 1 10 years were compared in a retrospective cohort study. After age matching, 
291 datasets from 2000 2CO2 were identified for each of 167 ECD, 171 LCD and 
144 NBS patient cohorts. Numbers of long term therapies (prescribed for >3 
months; LT; max 10), intravenous antibiotic ourses (IV) and nebulised therapies 
(NEB) were compared. To prevent bias by repeated measures, medians (using 
Mann Whitney two sample rank test) and proportions (coholts were considered 
large enough for the Central Limit Theorem to apply) were compared using the 
latest dataset for each patient. After age and ata collection year matching, 133 
patients per cobalt were identified. 
Results: For the 133 cohorts, NBS received fewer LT compared with LCD (median 
2 vs 3; p<0.CO2), but not ECD. Fewer NBS compared with LCD and ECD received 
IV (32 vs 57; p<0.CO1 and 32 vs 57; p<0.CO1). Fewer NBS compared with LCD 
received >2 NEB (13 vs 29; p~).005). For the 291 cohorts, age at which median 
NEB increased to 1 was 5, 8 and 7 years for LCD, NBS and ECD cohorts, 
respectively. 
Conclusions: NBS patients have a lower therapeutic burden and a longer duration 
free of NEB compared to ECD or LCD. 
